The OSM pathway also protects NSCLC cells harboring KRAS/EGFR mutations and EML4-ALK fusions from apoptosis via activation of OSMRs/JAK1/STAT3 signaling [200]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.